AstraZeneca Defends Pulmicort Patents At Fed. Circ.
AstraZeneca PLC on Monday asked the Federal Circuit to block four generic-drug makers from launching no-name versions of its Pulmicort Respules pediatric asthma medication, saying a lower court relied too heavily...To view the full article, register now.
Already a subscriber? Click here to view full article